BioTuesdays

Category - Markets

Alpine Immune Sciences

HCW starts Alpine Immune Sciences at buy; PT $21

H.C. Wainwright launched coverage of Alpine Immune Sciences (NASDAQ:ALPN) with a “buy” rating and $21 price target. The stock finished at $14.57 on Dec. 18. Alpine is leading the way in developing protein-based...

Arbutus Biopharma Logo

HCW starts Arbutus Biopharma at buy; PT $10

H.C. Wainwright launched coverage of Arbutus Biopharma (NASDAQ:ABUS) with a “buy” rating and price target of $10. The stock closed at $4.41 on Dec. 16. Arbutus is primarily focused on discovering, developing and...

Cycle-Therapeutics-Logo

Maxim starts Cyclo Therapeutics at buy; PT $12

Maxim Group initiated coverage of Cyclo Therapeutics (NASDAQ:CYTH) with a “buy” rating and $12 price target. The stock closed at $3.85 on Dec. 16. Cyclo is developing a Phase 3-ready hydroxypropyl beta cyclodextrin...

cohbar-logo

Chardan starts CohBar at buy; PT $3

Chardan Research launched coverage of CohBar (NASDAQ:CWBR) with a “buy” rating and price target of $3. The stock closed at $1.29 on Dec. 16. “We expect that Cohbar’s unique pipeline of mitochondrial derived...

X4 Pharma

Brookline starts X4 Pharma at buy; PT $21

Brookline Capital Markets launched coverage of X4 Pharmaceuticals (NASDAQ:XFOR) with a “buy” rating and $21 price target. The stock closed at $6.10 on Dec. 16. X4 Pharmaceuticals is focused on diseases resulting from...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.